Comparative Bioavailability Study of Azithromycin 200mg/5mL Suspension Following a 600mg Dose Under Fed Conditions
Launched by SANDOZ · Apr 3, 2009
Trial Information
Current as of May 24, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • No clinically significant findings on physical exam, medial history or laboratory tests on screening
- Exclusion Criteria:
- • Positive test for HIV or hepatitis B and C
- • Treatment for Drug or alcohol abuse
- • Any other important criteria in the protocol
About Sandoz
Sandoz, a global leader in generic pharmaceuticals and biosimilars, is committed to advancing healthcare by providing high-quality, affordable medications that enhance patient access to essential treatments. As a division of Novartis, Sandoz leverages innovative research and development to deliver a diverse portfolio of products across various therapeutic areas, including oncology, immunology, and cardiovascular health. The company prioritizes rigorous clinical trials to ensure the safety and efficacy of its offerings, fostering collaboration with healthcare professionals and regulatory bodies to meet the evolving needs of patients worldwide. Through its dedication to quality and sustainability, Sandoz aims to improve health outcomes and contribute to more efficient healthcare systems globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials